AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
30 Winter Street
Boston
Massachusetts
02108
United States
444 articles with AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
-
AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference
5/18/2022
AVEO Oncology announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time.
-
AVEO Oncology Reports First Quarter 2022 Financial Results
5/5/2022
AVEO Oncology today reported financial results for the first quarter ended March 31, 2022.
-
AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022
4/28/2022
AVEO Oncology today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022.
-
AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results
3/14/2022
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the fourth quarter and full year ended December 31, 2021, and provided financial guidance for 2022.
-
AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022
3/7/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022.
-
AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma
2/14/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that new long-term progression free survival (PFS) data from the Phase 3 TIVO-3 study, which compares FOTIVDA® (tivozanib) to Nexavar® (sorafenib) in advanced renal cell carcinoma (RCC) patients following two or more prior systemic therapies, are being presented at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
-
AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium
1/20/2022
AVEO Oncology announced that new efficacy and safety data from the first line of the phase 1b/2 DEDUCTIVE study of FOTIVDA® in combination with IMFINZI® in previously untreated metastatic hepatocellular carcinoma are being presented at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
-
Clinical Catch-Up: January 3-7
1/10/2022
The biopharma industry has started 2022 with plenty of clinical trial news. Here’s a look. -
AVEO Oncology Highlights Recent Progress and 2022 Outlook
1/4/2022
AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.
-
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
1/4/2022
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it has entered into a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany to evaluate ficlatuzumab in combination with ERBITUX ® (cetuximab), an EGFR-targeted antibody, in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ficlatuzumab is AVEO’s investigational potent
-
AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference
12/22/2021
AVEO Oncology today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th.
-
BioSpace Movers & Shakers, Dec. 3
12/3/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer
12/1/2021
AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer.
-
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences - Nov 10, 2021
11/10/2021
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, announced that members of its senior management team will participate in two upcoming virtual investor conferences.
-
AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update
11/8/2021
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the third quarter ended September 30, 2021 and provided a business update.
-
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
11/1/2021
AVEO Oncology to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 8, 2021
-
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma
9/20/2021
AVEO Oncology today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC).
-
AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences
8/30/2021
AVEO Oncology announced that members of its senior management team will participate in two upcoming virtual investor conferences.
-
AVEO Oncology Reports Second Quarter 2021 Financial Results and Provides Business Update
8/5/2021
AVEO Oncology, a commercial stage, oncology-focused biopharmaceutical company, reported financial results for the second quarter ended June 30, 2021, and provided a business update.